drugset
drugset / Trial / NCT06937866

Maintenance Zanzalintinib With Etoposide After HDCT in GCT

NCT06937866 ↗

Phase 1/2 Recruiting 38 enrolled Indiana University Exelixis · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

This is an open label, single arm phase I/II trial of maintenance zanzalintinib in combination with oral etoposide in patients with relapsed GCT treated with HDCT and PBSCT with a safety lead-in cohort in patients with relapsed, refractory metastatic GCT.

Timeline

Start
2025-11-12
Primary completion
2030-03
Completion
2031-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Zanzalintinib Small molecule 40 mg Oral
Subject Zanzalintinib Small molecule 60 mg Oral
Background Etoposide Small molecule — Oral

Indications

germ cell tumor